Biotech News
Related news
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-05-05 11:00 EST
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
ENTAEnanta Pharmaceuticals2025-11-17 21:01 EST
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
SPROSpero Therapeutics2026-03-18 16:05 EST
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
VIRIVirios Therapeutics2026-03-18 12:30 EST
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ANTXAN2 Therapeutics2026-03-17 20:00 EST
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
IMNNImunon2026-08-04 12:00 EST
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
IMNNImunon2026-05-05 12:30 EST
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
ABUSArbutus2026-03-23 11:30 EST
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Atea
Antiviral Therapeutics Company Atea Pharmaceuticals develops oral antiviral combinations for serious viral diseases. Hepatitis C Regimen The lead regimen combines nucleotide polymerase inhibitor bemnifosbuvir with NS5A inhibitor ruzasvir as a short-duration, ribavirin-free treatment for hepatitis C. Global Phase 3 Program C-BEYOND covers...
Recent company news
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
AVIRAtea2026-06-25 11:00 EST
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
AVIRAtea2026-05-27 11:00 EST
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Stock data
- Close
- 4.99 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States